THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma

Chemotherapy with gemcitabine plus cisplatin remains the mainstay of treatment for metastatic urothelial carcinoma (UC); however, drug resistance occurs in most patients and eventually leads to treatment failure. In this study, we investigated the role of cyclin-dependent kinase 7 (CDK7) regulation...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Cancer Res
Autors principals: Kuo, Kuan-Lin, Lin, Wei-Chou, Liu, Shing-Hwa, Hsu, Fu-Shun, Kuo, Yu, Liao, Shih-Ming, Yang, Shao-Ping, Wang, Zuo-He, Hsu, Chen-Hsun, Huang, Kuo-How
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7840706/
https://ncbi.nlm.nih.gov/pubmed/33520367
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars